<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir is thus the second major drug against COVID-19 with promising results according to the studies provided by Gilead, but which still awaits a definite confirmation. An inhalatory administration of remdesivir is going expected to be evaluated in a clinical trial beginning with August 2020, while other multiple clinical trials are examining the intravenous administration of remdesivir (WHO Solidarity trial, DisCoVeRy trial-France, ACTT-II-US).</p>
